AsemconnectVietnam - Pre-tax profit reached VND436 billion, an increase of 230% over the same period last year and equal to 130% of the 2023 plan.

Vietnam Pharmaceutical Corporation (Vinapharm - DVN code: UPCoM) said that the total revenue realized in 2023 reached VND306 billion, an increase of 74% compared to realized in 2022 and reaching 110% compared to the plan; Pre-tax profit is expected to reach VND222 billion, up 705% over the same period and reaching 105% of the plan.
Vinapharm's consolidation results show that total revenue is estimated at VND5,664 billion, equivalent to 2022 and reaching 96% of the plan. Pre-tax profit reached VND436 billion, an increase of 230% over the same period last year and equal to 130% of the 2023 plan.
Vinapharm has completed the development of a restructuring project with the goal of optimizing business operations, management and promoting sharing in SCIC's pharmaceutical portfolio.
In 2024, Vinapharm sets a revenue plan according to the general financial report of VND319 billion, an increase of 4% and pre-tax profit of VND254 billion, an increase of 14% compared to the estimate for 2023. Revenue according to the financial report Vinapharm's consolidated capital in 2024 is expected to be VND5,903 billion, equivalent to a 4% increase compared to the estimate for 2023. Pre-tax profit is expected to be VND524 billion, equivalent to an increase of 20% compared to the estimate for 2023.
N.Nga
Source: VITIC/Tinnhanhchungkhoan